Search

Eli Lilly and Co.

Atvērts

SektorsVeselības aprūpe

1,435.72 -0.54

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1440.09

Max

1474.75

Galvenie mērījumi

By Trading Economics

Ienākumi

-644M

6.5B

Pārdošana

1.4B

24B

P/E

Sektora vidējais

43.945

68.089

EPS

7.48

Dividenžu ienesīgums

0.49

Peļņas marža

26.442

Darbinieki

50,000

EBITDA

-3.7B

9.3B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+5.31% upside

Dividendes

By Acuity

Dividenžu ienesīgums

Sektora vidējais

0.49%

1.98%

Nākamie ieņēmumi

2027. g. 3. febr.

Nākamais dividenžu datums

2026. g. 10. dec.

Nākamais Ex dividenžu datums

2027. g. 12. febr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

118B

1.3T

Iepriekšējā atvēršanas cena

1436.26

Iepriekšējā slēgšanas cena

1435.72

Eli Lilly and Co. Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 14. nov. 01:01 UTC

Eli Lilly and Company shares are declining in after-market trading, having pulled back from a brief peak shortly after the market closed.

2026. g. 13. nov. 23:01 UTC

Eli Lilly and Company shares are modestly lower in after-market trading, reflecting a broadly declining market amid rising inflation concerns and Treasury yields.

2026. g. 12. nov. 23:02 UTC

Eli Lilly and Company shares are trading lower in after-market hours, reflecting a slight decline since Thursday's close, despite strong one-month gains.

2026. g. 11. nov. 23:03 UTC

News
Event

Eli Lilly reports positive results from the TOGETHER-PsA trial, showing Taltz and Zepbound's efficacy in treating psoriatic arthritis with weight-related comorbidities.

2026. g. 9. nov. 21:04 UTC

Social Media
Event
News

Eli Lilly reports positive Phase 3 trial results for Foundayo, showing significant reductions in obstructive sleep apnea severity among adults with obesity or overweight.

2026. g. 7. nov. 00:02 UTC

Event

Eli Lilly and Company announces agreement with Hims & Hers Health to expand access to medications Zepbound and Foundayo.

2026. g. 6. nov. 23:02 UTC

Event

Eli Lilly announces agreement with Hims & Hers to enhance access to medications Zepbound and Foundayo, with shares trading roughly flat in after-market hours.

2026. g. 5. nov. 23:03 UTC

Eli Lilly shares are trading modestly lower in after-market hours, reflecting a broader market decline amid significant drops in major semiconductor stocks.

2026. g. 4. nov. 23:02 UTC

Eli Lilly and Company shares gained modestly in after-market trading, remaining near the upper end of their one-month range following fluctuating returns.

2026. g. 3. nov. 23:01 UTC

Eli Lilly and Company shares are trading modestly lower in after-market hours, retreating from a brief peak earlier in the session.

2026. g. 2. nov. 23:06 UTC

Eli Lilly and Company is experiencing a modest increase in after-market trading, gaining slightly since Monday's close and positioned above its 20-day moving average.

2026. g. 30. okt. 23:01 UTC

Social Media
News

JP Morgan maintains Overweight rating on Eli Lilly and raises price target to $165, with shares trading modestly higher in after-market hours.

2026. g. 29. okt. 23:03 UTC

Eli Lilly and Company shares advanced during after-market hours, reflecting a broader upward trend in the Pharmaceuticals sub-sector.

2026. g. 28. okt. 23:02 UTC

Event
Social Media

Eli Lilly announces positive topline results from its Phase 3 trial comparing retatrutide to Ozempic in adults with type 2 diabetes.

2026. g. 27. okt. 20:07 UTC

Social Media
News

Eli Lilly announces a fourth-quarter 2026 dividend of $1.73 per share and reports strong Q2 results with net income of $7.09 billion.

2026. g. 23. okt. 20:02 UTC

Social Media
News
Correlated Moves

Eli Lilly and Co shares are declining, continuing a downward trend since Thursday's close, while the broader Pharmaceuticals sector is also lower.

2026. g. 22. okt. 20:07 UTC

Correlated Moves
Social Media
News

Eli Lilly breaks ground on a $5 billion manufacturing facility in Virginia, expected to create 650 permanent jobs and support U.S. manufacturing initiatives.

2026. g. 21. okt. 20:07 UTC

News
Correlated Moves

Leerink Partners raised Eli Lilly's price target to $1.32k, while RBC Capital set a target of $1.5k, but shares are declining in today's session.

2026. g. 20. okt. 23:02 UTC

News

Eli Lilly named RBC Capital's preferred pharmaceutical stock with a $1.5K price target, despite shares declining modestly in after-market hours.

2026. g. 19. okt. 23:06 UTC

Event

Eli Lilly announces positive Phase 3 SHINE-2 study results for Omvoh in pediatric ulcerative colitis, with 81% of participants achieving clinical response at Week 12.

2026. g. 17. okt. 00:01 UTC

Eli Lilly and Co shares are lower in after-market hours, reflecting broader market declines amid stronger-than-expected inflation metrics and significant inflows in U.S. TIC Flows.

2026. g. 16. okt. 23:06 UTC

Eli Lilly and Co shares are trading slightly lower in after-market hours, reflecting routine fluctuations amid a stable broader market context.

2026. g. 15. okt. 23:11 UTC

Social Media
Event

Eli Lilly announces new data showing treatment goals achieved for ulcerative colitis and Crohn's disease patients with Omvoh after one year.

2026. g. 14. okt. 23:42 UTC

Social Media

Eli Lilly and Co's shares are trading lower in after-market hours, reflecting a broader market decline amid rising Treasury yields and inflation concerns.

2026. g. 13. okt. 20:02 UTC

News
Correlated Moves
Social Media

Eli Lilly announces a clinical trial collaboration with Prelude Therapeutics for a Phase 1 trial involving abemaciclib and imlunestrant, contributing to bearish sentiment.

2026. g. 12. okt. 20:07 UTC

News
Event
Social Media

Eli Lilly gains support as RBC Capital reiterates Outperform rating with a $1.5K price target, following new data from the TOGETHER-PsO Phase 3b trial.

2026. g. 9. okt. 20:07 UTC

Social Media
Event
News
Correlated Moves

Eli Lilly presents new data from its Phase 3b TOGETHER-PsO trial, showing significant biomarker changes with the combination of Taltz and Zepbound for psoriasis treatment.

2026. g. 8. okt. 23:05 UTC

Eli Lilly and Co shares are trading lower in after-market hours, reflecting a decline since Thursday's close and fluctuating near the lower end of its recent range.

2026. g. 7. okt. 23:06 UTC

Eli Lilly and Co is trading slightly higher in after-market hours, remaining above its 20-day moving average and near the upper end of its one-month trading range.

2026. g. 6. okt. 20:07 UTC

Social Media
News
Event

Eli Lilly contributed to a $120 million Series B funding round for General Medicine, raising total funding to $152 million, amid positive market sentiment.

Salīdzinājums

Cenas izmaiņa

Eli Lilly and Co. Prognoze

Cenas mērķis

By TipRanks

5.31% augšup

Prognoze 12 mēnešiem

Vidējais 1,520.136 USD  5.31%

Augstākais 1,700 USD

Zemākais 940 USD

Pamatojoties uz 24 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Eli Lilly and Co. — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

24 ratings

22

Pirkt

1

Turēt

1

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
help-icon Live chat